Therapeutic advances in infectious disease · 2026
Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamato Masaya, Kinoshita Masahiro, Yoshida Yuki, Yamamoto Yudai, Izuhara Rie, Sonoyama Takuhiro
Аннотация
BACKGROUND: Immunocompromised patients have a risk of severe COVID-19.
OBJECTIVES: To describe the outcomes of ensitrelvir in hospitalized immunocompromised patients with COVID-19, with remdesivir as a reference.
DESIGN: Single-center retrospective cohort study.
METHODS: We analyzed patients with moderate/severe immunodeficiency who received ensitrelvir or remdesivir as initial therapy. The primary outcome was 28-day all-cause mortality; secondary outcomes were time to discharge and viral clearance. Exploratory analyses used inverse probability of treatment weighting (IPTW) based on propensity scores and Cox proportional-hazards models.
RESULTS: Among 56 patients (22 ensitrelvir; 34 remdesivir), 28-day mortality was 4.5% versus 8.8%, respectively. Time to discharge and viral clearance were similar. IPTW-adjusted 28-day mortality was 4.2% with ensitrelvir and 10.7% with remdesivir (hazard ratio 0.39; 95% CI 0.04-3.64).
CONCLUSION: In this small, single-center exploratory cohort, ensitrelvir was associated with low mortality, although comparison with remdesivir should be interpreted cautiously given treatment selection, treatment switching, and limited sample size.
OBJECTIVES: To describe the outcomes of ensitrelvir in hospitalized immunocompromised patients with COVID-19, with remdesivir as a reference.
DESIGN: Single-center retrospective cohort study.
METHODS: We analyzed patients with moderate/severe immunodeficiency who received ensitrelvir or remdesivir as initial therapy. The primary outcome was 28-day all-cause mortality; secondary outcomes were time to discharge and viral clearance. Exploratory analyses used inverse probability of treatment weighting (IPTW) based on propensity scores and Cox proportional-hazards models.
RESULTS: Among 56 patients (22 ensitrelvir; 34 remdesivir), 28-day mortality was 4.5% versus 8.8%, respectively. Time to discharge and viral clearance were similar. IPTW-adjusted 28-day mortality was 4.2% with ensitrelvir and 10.7% with remdesivir (hazard ratio 0.39; 95% CI 0.04-3.64).
CONCLUSION: In this small, single-center exploratory cohort, ensitrelvir was associated with low mortality, although comparison with remdesivir should be interpreted cautiously given treatment selection, treatment switching, and limited sample size.